Immersive AI Platform for Pathologists Set to Launch at CAP25 in Orlando
'It's no risk, no pressure. Just discovery,' said CAP President Donald Karcher, MD, FCAP. 'This initiative is about giving pathologists a trusted environment to evaluate new tools and stay in control of how technology fits into pathology practice.'
The College of American Pathologists' (CAP) platform, powered by PathPresenter's technology, will provide CAP members a safe, simulated space to explore cutting-edge AI tools used in pathology. From image analysis to diagnostic support, pathologists can interact with models in realistic patient scenarios without impacting care.
'It's no risk, no pressure. Just discovery,' said CAP President Donald Karcher, MD, FCAP. 'This initiative is about giving pathologists a trusted environment to evaluate new tools and stay in control of how technology fits into pathology practice.'
Designed as both an educational tool and a discovery hub, the platform is set to become a go-to destination for pathologists exploring AI in real-world contexts when launched at CAP25.
'We wanted to give pathologists a space to explore how AI models can be used in real-world practice,' said M. E. (Doc) de Baca, MD, FCAP, CAP Council on Informatics and Pathology Innovation Chair. 'This platform not only highlights the AI tools currently available and also offers a glimpse of what's possible as we continue to investigate how AI can support and enhance the practice of pathology.'
The platform will feature a slate of AI tools for the pathology community to test drive, with participation from vendors across the industry. Pathologists will be able to engage with real models, not just screenshots or quick demos. It's designed to meet the growing demand for meaningful, hands-on exploration of AI tools in a setting that supports learning and confidence.
'Pathologists are looking for more than marketing jargon,' said Rajendra Singh, MD, FCAP, co-founder of PathPresenter. 'They want evidence. They want to see first-hand how these tools perform, what problems they solve, and how they fit into real pathology workflows. This platform brings together the best of both worlds: innovative AI models and expert users who know how to critically evaluate them.'
The initiative is guided by CAP leaders at the forefront of informatics, AI, and digital innovation, bringing deep expertise and a clear focus on what pathologists need most from emerging technologies.
About the College of American Pathologists
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, CAP.org and yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care.
About PathPresenter
PathPresenter is an enterprise image management and workflow platform for digital pathology. We are on a mission to democratize access to the world's pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded by dermatopathologist and digital pathology pioneer Dr. Rajendra Singh, PathPresenter's secure, scalable, vendor-agnostic enterprise pathology workflow software has been adopted by tier one medical institutions for clinical care, education, and research, and the company has built a thriving community of tens of thousands of users around the world to easily view and share digital pathology images and knowledge. Learn more at www.pathpresenter.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
BostonGene Publishes Landmark Study Providing Clinical and Analytical Validation for Its Multimodal RNA and DNA Assay
WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced the publication of a pivotal study, ' Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort, ' in Communications Medicine, a high-impact journal in the Nature portfolio. The study underscores the BostonGene Tumor Portrait™ assay as a clinically robust, regulatory-grade platform that forms the foundation of BostonGene's AI-powered platform, purpose-built for precision oncology and designed to accelerate therapeutic development and enhance clinical data collection. 'Delivering clinically validated multimodal data from a single tumor sample—and interpreting it through an immune-focused, AI-enabled lens—represents a transformative advancement for oncology drug development.' The Tumor Portrait™ assay integrates DNA and RNA sequencing into a single end-to-end test, delivering a multimodal view of each tumor. Approved under CLIA, CAP and the New York State Department of Health, the platform enhances patient stratification, predictive biomarker discovery and clinical trial enrollment—all critical to reducing the risks associated with drug development and improving clinical trial success rates. The study details the implementation of highly stable clinical RNA-seq protocol, deployed in ready-to-use clinical settings and tested across more than 2,200 tumors, demonstrating high reproducibility, strong clinical actionability (98% of cases) and advanced detection of alterations, fusions, immune signatures, tumor microenvironment profiles and AI-based predictive classifications. 'Delivering clinically validated multimodal data from a single tumor sample—and interpreting it through an immune-focused, AI-enabled lens—represents a transformative advancement for oncology drug development,' said Alexander Bagaev, PhD, Chief Product Officer at BostonGene. 'By combining DNA and RNA sequencing in one assay, our platform enables deeper biological understanding of the tumor microenvironment and genetics, smarter patient selection and more confident, data-driven decisions throughout the drug development lifecycle. This validation sets a new benchmark for translational research and diagnostic innovation.' About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit
Wall Street Journal
4 days ago
- Wall Street Journal
Robinhood On Pace to Cross $100 Billion Market Cap
The digital brokerage with meme-stock origins is on pace to close above the $100 billion market cap threshold for the first time today, with the share price also on track to notch a new record. The stock is up more than 200% so far this year.
Bloomberg
7 days ago
- Bloomberg
AI Boom Leads to Exploding Valuations
00:00 We look at something like Palantir, a 500% in 12 months, the most expensive stock on the S & P 500 when you're looking at where it prices versus future sales. Does it seem vindicated to you, these sorts of valuations? There's absolutely some enthusiasm at play here. And I think there's some and I think in this earnings season, we have heard from a variety of companies, not just these mega-cap tech companies, that they're seeing early signs of success with AI. AI's helping them run more efficiently. It's writing more and more of their code, something like 50% of code. And it's also helping them hit more shots on target, particularly in marketing. But beyond that, I think when it comes to valuations, you need to on one end look at the stability and the core business operations of some of these companies is mega-cap tech companies which remain highly profitable and then also some of the upside moving forward in the AI race. And when it comes to the leading mega-cap tech companies, at least we actually think valuations aren't as overstretched because core earnings are so robust and they are actively reinvesting a lot of those profits that cash flow into the next paradigm shift. And we're already seeing some early signs of success. These picks and shovels companies, they're also digging for gold and seeing the fruits of that. Stephanie, when you were last with us in April, it was just after the sort of deep sea chaos and we discussed how the semiconductor industry in particular was in the crosshairs of the administration. A lot has changed since then. Actually, the administration has been very supportive in exporting American technology. But just on the stories we touched on tariffs on semiconductors and location tracking on chips, there's a risk premium there. Is that. Absolutely. Geopolitics remains a risk. Policy has been a headwind for the sector in recent months and particularly today. But we are seeing a shift from this administration towards a greater appreciation around what safeguarding US dominance in AI really looks like. Right. And I will add, outside of these risks around tariffs. What is really promising and quite structural is that you have seen a decline in over 90% around the cost of inference for AI, and that has to do with four factors. Hardware, the chips themselves have been getting significantly more efficient. Algorithms are getting more efficient. How much data, how many numbers they need to crunch or right sizing models. We now have mini models that we can access. And we've seen this democratization in models, particularly open source. So all of that has led to this pretty remarkable decline in the costs of AI. And I think we need to put that to one side when thinking about these risks for tariffs. We shall borrow that acronym going forward. What I've wanted to ask you for a long time. Is there an America ink trade going on here where you just say, I bet on these companies that are most likely to succeed if this American strategy pays off? I think it's a really interesting point, particularly in the context of this debate around U.S. exceptionalism, because when I look at the markets right now, I don't see so much U.S. exceptionalism, but exceptionalism from a few US companies. And that is really what is driving the markets right now. We're actually less concerned about valuations for, let's say, the Magnificent Seven and a bit more concerned about the other 493, because without that structural tailwind, when it comes to AI, it's a bit harder to see the cyclical tailwinds for the rest of the market. But when it comes to these leading tech companies, I think you do have unprecedented fundamentals and the continued dominance, particularly in tech services. Now, there's plenty for investors to consider and we still think portfolios should be diversified. But at a time like this, you maybe don't want to be diversifying away from that epicenter of innovation. Okay. So interesting that you got the acronym POD. Hard Tech is where everyone's looking at it from a startup culture, but also into these big magnificent seven, but then drip feed it down into where if you are going to diversify the sectors that are deploying it right or indeed is it more about the picks and shovels, a little bit more about the energy, It's about the infrastructure on that side of the equation that keeps you in the air spin? Absolutely. The value chain is continuing to expand. We think that infrastructure layer is huge and that is a secular story that is still in its early innings. The amount of energy that we're going to need, the investment that we're going to need in a variety of different sources and also everything that goes into those data centers themselves, the cooling equipment, the server technology and so forth. So we still think there's a significant investment case there. But what's also really interesting, particularly what we're seeing in private markets this year, is this explosion of AI applications, the kind of applications that businesses are going to need because it's not enough to give the workers strategy, but they need domain specific applications that are actually productivity enhancing and show up in the bottom line. We're seeing more and more of those come to market this year, mostly in private markets. But I think that's a trend that is worth watching and just getting going. And then they move from private markets into public markets. And we see what happened with Figma and the euphoria around that particular listing. Are you seeing more of your clients wanting to know about what IPOs to get into or indeed how to make that move from private markets into public markets? I think there's a lot of interest there as there should be. I mean, there's a lot of anticipation for a pickup in IPO activity. And I think the fundamentals and the promise and a lot of those AI startups could be the thing that really gets enthusiasm and comfort going in the market again. But I also don't think that we're going to go back to that kind of post-pandemic period. A lot of these companies have different goals beyond just being profitable companies, right? Many of the loan providers that are in private markets, they're on the race to AGI. And so there is also this appreciation that these companies can get a lot of the capital that they need in private markets. Maybe they want more control over their companies. So if you want to access that opportunity set, don't just wait for them to go public. I think you might want to look at your private market exposure and then also maybe some of those taxable opportunities that do arise this year.
